Nuclear medicine. A new radiopharmaceutical drug, Rakurs 223Ra, has entered the Russian market. Its active component is the radionuclide radium-223 manufactured by Rosatom. All technologies for manufacturing this valuable isotope, developed by Russian nuclear scientists, are patented. The drug will be used to treat certain types of cancer, primarily bone metastases. According to medical assessments, patients receiving this treatment can expect sustained remission, reduced pain, and improved quality of life. The first batch of the medication has already been delivered to medical institutions across the country. Rosatom is scaling up production of a broad range of medical equipment and radiopharmaceuticals, working to build a comprehensive system for delivering advanced nuclear medicine care.